An Early Phase 1 interventional study of Yang Yin Fu Zheng Jie Du therapy and Routine medical care in Hepatocellular Carcinoma, sponsored by Beijing Ditan Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-13.
Sponsored by Beijing Ditan Hospital · Early Phase 1, Interventional, and Treatment
Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV associated Hepatocellular Carcinoma based on the platelet count/splenic length-diameter ratio.The purpose of this study is to establish the efficacy evaluation system combined with platelet/splenic length-diameter ratio, and to clarify the effect of this method on relieving hepatitis B cirrhosis and delaying the progression of Hepatocellular Carcinoma.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 108 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →Beijing Ditan Hospital is the lead sponsor of 52 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Meet the criteria of hepatocellular carcinoma Patients who tested positive for hepatitis B surface antigen (HBsAg) for >6 months Liver function grade child-Pugh A/B Patients who have agreed to select local treatment according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2017) TCM syndrome differentiation belongs to deficiency of qi and Yin, stasis and toxin accumulation syndrom Informed consent from the patient.
Exclusion Criteria:
Patient with other hepatitis virus infections or alcoholic liver, autoimmunity liver, primary biliary cirrhosis, genetic metabolic liver disease, and previous liver transplantation; Serious problem of heart, lung, brain, blood and other important organs; Patients with metastatic liver cancer; Pregnant or child breast feeding women; Mental or cognitive disorders; Who are allergic to the study drug.
Drug: Yang Yin Fu Zheng Jie Du therapy
Drug: Routine medical care
Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Routine medical care
Tumor progression rate
Time frame: 1 year
Overall survival rate
Time frame: 1 year
Progression-free survival rate
Time frame: 1 year
Median time to tumor progression
Time frame: 1 year
Complete response rate
Time frame: 1 year
the platelet count/splenic length-diameter ratio
Time frame: 1 year
quality of life (QOL) questionnaire
Time frame: 1 year
This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Ditan Hospital